• Known active ingredient as new drug cand

    From ScienceDaily@1:317/3 to All on Wed Mar 22 22:30:26 2023
    Known active ingredient as new drug candidate against mpox

    Date:
    March 22, 2023
    Source:
    Goethe University Frankfurt
    Summary:
    Mpox -- previously known as 'monkeypox' -- is currently spreading
    worldwide. Researchers have now identified a compound that could
    help fight the disease.


    Facebook Twitter Pinterest LinkedIN Email
    FULL STORY ==========================================================================
    Mpox -- previously known as "monkeypox" -- is currently spreading
    worldwide. An international research team from Goethe University and
    the University of Kent has now identified a compound that could help
    fight the disease. Their study has been published in the Journal of
    Medical Virology.


    ========================================================================== Nitroxoline is the name of the new drug candidate that could potentially
    be used to treat mpox. It was identified by scientists at Goethe
    University and the University of Kent as part of a multi-site study. The results of their research will now allow clinical trials to begin soon.

    The current mpox outbreak is the first of this size to occur outside
    of Africa and also the first mpox outbreak caused by human-to-human transmission. People with immunodeficiencies are particularly at risk
    from the disease. Although antiviral agents have already been shown
    to inhibit the replication of the mpox virus in experimental models,
    the efficacy of these substances has not yet been confirmed in humans
    and some may have significant side effects. In addition, there are
    insufficient stocks to treat all mpox patients. Moreover, resistance
    formation against tecovirimat, the most promising mpox drug candidate
    to date, has already been reported.

    In the present study, the international team led by Professor Jindrich
    Cinatl (of Goethe University Frankfurt and the Dr. Petra Joh-Research Institute) and Professor Martin Michaelis (School of Biosciences,
    University of Kent) has identified nitroxoline, a well-tolerated
    antibiotic, as a potential treatment alternative for the mpox virus
    based on experiments using cell culture and skin explant models.

    Nitroxoline is also effective against a tecovirimat-resistant strain of
    the mpox virus, as well as other bacterial and viral pathogens that are frequently co-transmitted with mpox viruses, meaning it simultaneously suppresses multiple pathogens that are often involved in severe courses
    of mpox. Since nitroxoline is a well-tolerated antibiotic that has long
    been used to treat humans, it can be tested directly against mpox in
    clinical trials.

    "The emergence of resistant virus strains is a cause of great concern,"
    says Professor Jindrich Cinatl of Goethe University and the Dr. Petra Joh-Research Institute. "It is very reassuring that nitroxoline is
    effective against a tecovirimat-resistant virus." Professor Martin
    Michaelis of the University of Kent adds: "The more different drugs become available to treat viral diseases, the better. We hope that nitroxoline
    will turn out to be an effective treatment for mpox patients."
    * RELATED_TOPICS
    o Health_&_Medicine
    # Pharmacology # Viruses # Infectious_Diseases #
    HIV_and_AIDS
    o Plants_&_Animals
    # Virology # Microbes_and_More # Biology # Bacteria
    * RELATED_TERMS
    o Huntington's_disease o Prion o Mumps o Stem_cell_treatments
    o Alzheimer's_disease o Neoteny o Air_pollution o
    Legionnaires'_disease

    ========================================================================== Story Source: Materials provided by Goethe_University_Frankfurt. Note:
    Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Denisa Bojkova, Nadja Zo"ller, Manuela Tietgen, Katja Steinhorst,
    Marco
    Bechtel, Tamara Rothenburger, Joshua D. Kandler, Julia Schneider,
    Victor M. Corman, Sandra Ciesek, Holger F. Rabenau, Mark N. Wass,
    Stefan Kippenberger, Stephan Go"ttig, Martin Michaelis, Jindrich
    Cinatl.

    Repurposing of the antibiotic nitroxoline for the treatment of mpox.

    Journal of Medical Virology, 2023; 95 (3) DOI: 10.1002/jmv.28652 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2023/03/230322190939.htm

    --- up 1 year, 3 weeks, 2 days, 10 hours, 50 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)